Instil Bio Q2 net loss narrows on lower R&D spending, restructuring charges
Brief: Instil Bio Q2 Basic EPS USD -0.63
Instil Bio, Inc. expected to post a loss of 43 cents a share - Earnings Preview
Instil Bio Q1 net loss narrows on lower R&D expenses
Instil Bio Q4 net loss per share narrows
Brief: Instil Bio Q4 Basic EPS USD -1.21
U.S. RESEARCH ROUNDUP-Alphabet, Hershey, Micron Technology
NASDAQ RESUMED AT 07:35 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Instil Bio Q3 net loss per share narrows
Instil Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Instil Bio Q2 Basic EPS USD -3.24
Instil Bio Inc expected to post a loss of $2.50 a share - Earnings Preview
Brief: Instil Bio Announces US FDA Clearance Of Investigational New Drug (Ind) Application For Axn-2510
Brief: Instil Bio Announces Appointment Of Jamie Freedman, M.D., Ph.D., As Chief Medical Officer
BioNTech climbs on cancer drug deal with Bristol Myers
U.S. STOCKS ON THE MOVE-Snowflake, Omnicell, Hinge Health
Advisory: Alerts incorrectly tagged to T Rowe Price Large-Cap Value Fund withdrawn
Brief: Instil Bio Q1 Basic EPS USD -4.32